OnKure Therapeutics (NASDAQ:OKUR) Releases Earnings Results, Beats Estimates By $0.05 EPS

OnKure Therapeutics (NASDAQ:OKUR) posted its quarterly earnings results on Wednesday. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.05, FiscalAI reports.

OnKure Therapeutics Price Performance

Shares of OKUR stock traded up $0.09 during trading on Wednesday, reaching $2.59. The company had a trading volume of 876,952 shares, compared to its average volume of 269,594. The firm’s 50 day simple moving average is $2.85 and its two-hundred day simple moving average is $3.59. OnKure Therapeutics has a one year low of $2.01 and a one year high of $5.38. The company has a market capitalization of $104.64 million, a PE ratio of -0.74 and a beta of 0.18.

Analysts Set New Price Targets

A number of brokerages have commented on OKUR. Oppenheimer restated an “outperform” rating and issued a $14.00 target price on shares of OnKure Therapeutics in a research note on Friday, August 14th. HC Wainwright dropped their target price on OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research report on Monday, July 20th. Finally, Weiss Ratings raised OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $17.50.

About OnKure Therapeutics

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.